Calley Means

Calley Means was born September 28, 1985, and raised in Washington, D.C., alongside his younger sister Casey. He attended Stanford University, where he studied political science and economics, and later earned an MBA from Harvard Business School.

He began his professional life inside Republican policy and political-economy institutions. He served as a White House intern during the second term of George W. Bush, interned at the Heritage Foundation, and later worked as a consultant advising food and pharmaceutical industry clients. He has publicly framed those industry-facing consulting years — and the conflicts of interest he observed inside health regulatory bodies — as the formative experience that turned him into a health-reform advocate.

In 2022, Means founded Truemed, a company that works with health-and-wellness merchants to help qualifying customers use pre-tax HSA/FSA dollars on eligible items by issuing letters of medical necessity. Truemed’s growth has also drawn scrutiny — media outlets have raised IRS-compliance questions about the letter-of-medical-necessity model and, later, conflict-of-interest questions about Means’s HHS role while Truemed remains active in the market.

Throughout the 2024 cycle, Means and his sister Casey served as close advisers to Robert F. Kennedy Jr.’s presidential campaign. After Kennedy suspended his independent run and endorsed Donald Trump in August 2024, both Means siblings became surrogates for the MAHA platform inside the Trump campaign. Their joint book Good Energy, released in 2024, ran the intellectual argument for metabolic dysfunction as the root of American chronic disease and anchored the coalition’s policy framing.

In early 2025, Calley Means was named a senior advisor at the U.S. Department of Health and Human Services, placing him inside the political decision-making apparatus of the Kennedy HHS rather than in a Senate-confirmed post. In that role he has been a visible public-facing voice for the MAHA agenda, appearing on cable news, podcasts, and in the congressional record on food-industry conflicts of interest.

His current battles include managing the Truemed conflict-of-interest scrutiny, translating movement-language priorities into actual HHS rulemakings, and serving as an unofficial bridge between the Kennedy inner circle and the broader coalition of podcasters, authors, and independent doctors who built the MAHA audience.

Open questions: whether his HHS post eventually evolves into a Senate-confirmed role, how the Truemed disclosure plays out if regulatory action affects HSA/FSA policy directly, and whether the sibling pairing of a Surgeon General nominee and a senior HHS advisor remains operational through 2026.